University of California San Francisco

The goal of gene therapy for severe hemophilia A patients is to decrease the annual bleed rate (ABR) and reduce the treatment burden of frequent prophylactic Factor VIII infusions, but hematologists a

Navigator Medicines unveiled its plans to develop novel medicines for complex, heterogeneous autoimmune diseases on 27 August, revealing that it has raised $100m in series A funding from RA Capital M

The first half of July brought an explosion of venture capital fireworks with several $100m-plus financings for biopharmaceutical companies, but the pace of mega-round announcements has fizzled out in

Investor interest in biopharmaceutical opportunities is slowly but surely improving in 2024, including both private investors and public-sector funders of drug development infrastructure. In mid-month